Related Experiment Video

Updated: May 21, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Polo-like kinases in AML

Tobias Berg, Gesine Bug, Oliver G Ottmann

    Expert Opinion on Investigational Drugs
    |June 7, 2012
    PubMed

    Insights

    New cancer therapies targeting the cell cycle, specifically Polo-like kinase 1 (Plk1) inhibitors, show promise for treating leukemia and solid tumors. Research highlights the role of Plk1 and Plk2 in acute myeloid leukemia (AML) treatment strategies.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Cancer Therapeutics

    Background:

    • The cell cycle is a critical target for novel cancer therapies.
    • Polo-like kinase 1 (Plk1) is a key regulator of mitosis and a promising target for cancer drug development.
    • Numerous clinical trials are investigating Plk1 inhibitors for solid tumors and leukemia.

    Discussion:

    • This review focuses on the roles of Plk1 and the potential tumor suppressor Plk2 in acute myeloid leukemia (AML).
    • Most cancers exhibit a dependency on Plk1, making it an attractive therapeutic target.
    • Understanding Plk1 and Plk2 functions is crucial for developing effective AML treatments.

    Key Insights:

    • Plk1 inhibitors are being evaluated in clinical trials for various cancers, including leukemia.
    • Plk1's essential role in mitosis makes it a vulnerability in many cancer types.
    • Plk2 may function as a tumor suppressor, offering additional therapeutic avenues in AML.

    Outlook:

    • Further research into Plk1 and Plk2 pathways could lead to more targeted and effective AML therapies.
    • The development of Plk1 inhibitors represents a significant advancement in cancer treatment strategies.
    • Investigating the interplay between Plk1 and Plk2 may unlock new therapeutic combinations for hematological malignancies.

    More Related Videos

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

    Published on: June 6, 2025

    Identification of Kinase-substrate Pairs Using High Throughput Screening11:13

    Identification of Kinase-substrate Pairs Using High Throughput Screening

    Published on: August 29, 2015

    Related Concept Videos

    PI3K/mTOR/AKT Signaling Pathway01:22

    PI3K/mTOR/AKT Signaling Pathway

    The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
    M-Cdk Drives Transition Into Mitosis02:15

    M-Cdk Drives Transition Into Mitosis

    Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
    Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
    M cyclin...
    Receptor Tyrosine Kinases01:26

    Receptor Tyrosine Kinases

    Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...